Katherine Hasal, MS

Articles

Novel NGS Test May Enhance Diagnosis and Management of Indeterminate Thyroid Nodules

November 2nd 2014

A next-generation sequencing assay has shown promise as a new tool to aid in the diagnosis and treatment of indeterminate thyroid nodules.

Next-Generation Sequencing Effectively Detects Cancer in Thyroid Nodules

November 2nd 2014

The ThyroSeq v2 next-generation sequencing assay was highly accurate at diagnosing cancer in thyroid nodules with follicular neoplasm or those suspected of follicular neoplasm cytology.

Vitamin D Levels Predict Hypocalcemia After Thyroid Cancer Treatment

November 1st 2014

Preoperative vitamin D deficiency is associated with postoperative symptomatic hypocalcemia in patients with thyroid cancer undergoing total thyroidectomy plus central compartment neck dissection.

Novel Therapeutic Target Identified in Aggressive Thyroid Cancers

November 1st 2014

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

New Assay Effectively Detects Circulating BRAFV600E in Patients With Papillary Thyroid Cancer

November 1st 2014

The detection of BRAFV600E in patients with papillary thyroid cancer using a blood-based assay was shown to be feasible in a cohort of patients undergoing thyroidectomy.

Moderate THST Improves Outcomes in Differentiated Thyroid Cancer

October 31st 2014

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

Disease-Related Variables Predictive of Outcomes With Sorafenib in DTC

October 31st 2014

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

PD-1 Immunotherapies Induce Painless Thyroiditis in Patients With Metastatic Malignancies

October 31st 2014

Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies